Enfusion, Inc. (NYSE:ENFN) Insider Bronwen Bastone Sells 2,064 Shares

Enfusion, Inc. (NYSE:ENFN) insider Bronwen Bastone sold 2,064 shares of Enfusion stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $11.48, for a total transaction of $23,694.72. Following the completion of the transaction, the insider now directly owns 225,001 shares of the company’s stock, valued at approximately $2,583,011.48. This represents a 0.91 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Bronwen Bastone also recently made the following trade(s):

• On Tuesday, January 7th, Bronwen Bastone sold 809 shares of Enfusion stock. The shares were sold at an average price of $10.13, for a total transaction of $8,195.17.

Enfusion Stock Up 0.4 %

ENFN stock opened at $11.45 on Thursday. The company has a market capitalization of $1.47 billion, a P/E ratio of 286.20, a PEG ratio of 1.85 and a beta of 0.96. The company has a 50-day simple moving average of $10.95 and a 200 day simple moving average of $9.85. Enfusion, Inc. has a fifty-two week low of $7.83 and a fifty-two week high of $11.80.

Enfusion (NYSE:ENFN) last issued its quarterly earnings results on Monday, March 3rd. The company reported $0.01 EPS for the quarter, missing the consensus estimate of $0.03 by ($0.02). Enfusion had a return on equity of 6.67% and a net margin of 1.70%. The business had revenue of $52.94 million during the quarter, compared to the consensus estimate of $53.98 million. Equities analysts anticipate that Enfusion, Inc. will post 0.06 EPS for the current year.

Institutional Investors Weigh In On Enfusion

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Centiva Capital LP raised its position in Enfusion by 5.0% in the third quarter. Centiva Capital LP now owns 25,596 shares of the company’s stock worth $243,000 after acquiring an additional 1,227 shares in the last quarter. Harbor Capital Advisors Inc. grew its holdings in shares of Enfusion by 12.4% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 11,887 shares of the company’s stock valued at $113,000 after acquiring an additional 1,315 shares in the last quarter. Mackenzie Financial Corp grew its holdings in shares of Enfusion by 4.8% during the 4th quarter. Mackenzie Financial Corp now owns 31,271 shares of the company’s stock valued at $322,000 after acquiring an additional 1,434 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Enfusion by 5.9% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 28,070 shares of the company’s stock valued at $289,000 after acquiring an additional 1,567 shares in the last quarter. Finally, Rhumbline Advisers lifted its stake in shares of Enfusion by 3.0% in the 4th quarter. Rhumbline Advisers now owns 62,464 shares of the company’s stock valued at $643,000 after purchasing an additional 1,796 shares during the last quarter. 81.05% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the stock. Piper Sandler boosted their price target on shares of Enfusion from $10.00 to $11.50 and gave the company a “neutral” rating in a report on Monday, December 23rd. Stifel Nicolaus boosted their price target on shares of Enfusion from $11.00 to $13.00 and gave the company a “buy” rating in a report on Wednesday, December 18th. Finally, William Blair reissued a “market perform” rating on shares of Enfusion in a report on Monday, January 13th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $11.13.

About Enfusion

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.